Search

everythinglearnresearchcommunity

for

Search:↓

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Anti-CD19 therapy may help treat SLE and NMOSD.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.

A new treatment plan for hair loss combines targeted therapies and regenerative strategies to stabilize, reverse, and maintain hair growth.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

The treatment was not recommended due to limited effectiveness and significant side effects.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Thermoresponsive nanogels show promise for delivering medicine through the skin but need more safety testing and regulatory approval before clinical use.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Certain microRNAs may help treat alopecia areata by targeting immune pathways.

Recombinant human TSG-6 speeds up wound healing in diabetic mice.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

The enzyme is crucial for skin cell development and can be activated without proteolytic activation.

Thiopurines help treat IBD but require genetic testing to avoid side effects.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.